Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data
Mayo Clinic · Norwegian Womens Public Health Association · +4 more institutions
Abstract
The blood-brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal brain. However, the importance of the BBB in limiting drug delivery and efficacy is controversial in high-grade brain tumors, such as glioblastoma (GBM). The accumulation of normally brain impenetrant radiographic contrast material in essentially all GBM has popularized a belief that the BBB is uniformly disrupted in all GBM patients so that consideration of drug distribution across the BBB is not relevant in designing therapies for GBM. However, contrary to this view, overwhelming clinical evidence demonstrates that there is also a clinically significant tumor burden with an intact BBB in all GBM, and there is little…
Citation impact
- FWCI
- 20.00
- Percentile
- 100%
- References
- 99
Authors
17- JNJann N. SarkariaCorresponding
Mayo Clinic, Norwegian Womens Public Health Association
- LHLeland Hu
Mayo Clinic in Arizona
- IFIan F. Parney
Mayo Clinic, Norwegian Womens Public Health Association
- DPDeanna Pafundi
Mayo Clinic, Norwegian Womens Public Health Association
- DHDebra H. Brinkmann
Mayo Clinic, Norwegian Womens Public Health Association
Topics & keywords
- Blood–brain barrier
- Glioblastoma
- Medicine
- Neuroscience
- Computer science
- Psychology
- Central nervous system
- Cancer research
- Good health and well-being